Former Rentschler-CEO Dr Frank Mathias officially takes up his new position as CEO and board member of Oxford Biomedica at the end of March.
Dr Mark Chadwick will bring extensive industry knowledge to his new role as Strategic Business Advisor at UK-based Ingenza Ltd.
France-based Abivax SA announced the appointment of Sheldon Sloan, M.D., M. Bioethics, as its new Chief Medical Officer. He will assume the new role in the beginning of March.
Dr Carole Nicco took up her position as CSO of Belgium-based BioSenic in mid-January. Nicco will oversee the development of BioSenic’s cell therapy and autoimmune disease platform pipeline and be responsible for R&D programmes.
At the beginning of January 2023?Marjut Falkstedt will start as new Chief Executive of the European Investment Fund (EIF).
Valneva has appointed Dipal Patel as new Chief Commercial Officer and Management Board member.
Dr Frank Mathias, currently CEO at Rentschler Biopharma, will join Oxford Biomedica as CEO and Board Director in March 2023.
At the beginning of november, OxSonics Therapeutics has appointed Jérôme Marzinski as its Chief Executive Officer.
Aurobac Therapeutics has appointed Florence Séjourné as CEO. The French company is a joint venture, founded by Boehringer Ingelheim, Evotec and bioMérieux and focuses on combating antimicrobial resistance (AMR).
Bioxodes SA,based in Marche-en-Famenne, Belgium, has appointed Marc Dechamps as its new CEO. Company founder, Edmond Godfroid, will take up the post of Chief Operations Officer (COO) alongside his existing responsibilities as Chief Scientific Officer (CSO).